pharma news today obesity drugs glp-1 today New Pills Are Coming, & Wegovy May Become an Implant! GLP-1s and the Unintended Consequences
Description
51 Addressing these adverse effects is crucial for improving patient compliance and therapeutic outcomes
Recent developments underscore the relevance of GLP-1R agonists in addressing the complex interplay of cardiovascular-kidney-metabolic (CKM) syndrome, microvascular dysfunction, and metabolic-associated steatohepatitis (MASH)
10.1016/j.mce.2010.04.022
What is GLP-1 Plus
Chakravarthy M, Arguelles-Tello FA, Sun ALA, Elliott M, Acosta L, Rankin JE, et al
